GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PDS Biotechnology Corp (NAS:PDSB) » Definitions » Cyclically Adjusted PB Ratio

PDS Biotechnology (PDS Biotechnology) Cyclically Adjusted PB Ratio : 0.17 (As of May. 23, 2024)


View and export this data going back to 2015. Start your Free Trial

What is PDS Biotechnology Cyclically Adjusted PB Ratio?

As of today (2024-05-23), PDS Biotechnology's current share price is $3.38. PDS Biotechnology's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $20.34. PDS Biotechnology's Cyclically Adjusted PB Ratio for today is 0.17.

The historical rank and industry rank for PDS Biotechnology's Cyclically Adjusted PB Ratio or its related term are showing as below:

PDSB' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 0.35
Current: 0.18

During the past years, PDS Biotechnology's highest Cyclically Adjusted PB Ratio was 0.35. The lowest was 0.00. And the median was 0.00.

PDSB's Cyclically Adjusted PB Ratio is ranked better than
83.56% of 651 companies
in the Biotechnology industry
Industry Median: 1.71 vs PDSB: 0.18

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

PDS Biotechnology's adjusted book value per share data for the three months ended in Mar. 2024 was $1.014. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $20.34 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


PDS Biotechnology Cyclically Adjusted PB Ratio Historical Data

The historical data trend for PDS Biotechnology's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PDS Biotechnology Cyclically Adjusted PB Ratio Chart

PDS Biotechnology Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 0.25

PDS Biotechnology Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 0.25 0.19

Competitive Comparison of PDS Biotechnology's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, PDS Biotechnology's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PDS Biotechnology's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PDS Biotechnology's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where PDS Biotechnology's Cyclically Adjusted PB Ratio falls into.



PDS Biotechnology Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

PDS Biotechnology's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=3.38/20.34
=0.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PDS Biotechnology's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, PDS Biotechnology's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=1.014/131.7762*131.7762
=1.014

Current CPI (Mar. 2024) = 131.7762.

PDS Biotechnology Quarterly Data

Book Value per Share CPI Adj_Book
201406 0.000 100.560 0.000
201409 0.000 100.428 0.000
201412 -36.866 99.070 -49.037
201503 0.000 99.621 0.000
201506 40.343 100.684 52.801
201509 -104.675 100.392 -137.399
201512 85.022 99.792 112.272
201603 79.632 100.470 104.445
201606 74.009 101.688 95.907
201609 67.444 101.861 87.251
201612 61.744 101.863 79.876
201703 54.218 102.862 69.458
201706 54.668 103.349 69.705
201709 48.384 104.136 61.227
201712 40.410 104.011 51.197
201803 28.342 105.290 35.472
201806 21.286 106.317 26.383
201809 19.781 106.507 24.474
201812 18.976 105.998 23.591
201903 4.726 107.251 5.807
201906 3.980 108.070 4.853
201909 2.952 108.329 3.591
201912 2.215 108.420 2.692
202003 1.296 108.902 1.568
202006 1.108 108.767 1.342
202009 1.394 109.815 1.673
202012 1.219 109.897 1.462
202103 1.094 111.754 1.290
202106 2.569 114.631 2.953
202109 2.386 115.734 2.717
202112 2.222 117.630 2.489
202203 1.964 121.301 2.134
202206 1.807 125.017 1.905
202209 1.654 125.227 1.741
202212 1.458 125.222 1.534
202303 1.335 127.348 1.381
202306 1.051 128.729 1.076
202309 0.790 129.860 0.802
202312 0.790 129.419 0.804
202403 1.014 131.776 1.014

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


PDS Biotechnology  (NAS:PDSB) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


PDS Biotechnology Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of PDS Biotechnology's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


PDS Biotechnology (PDS Biotechnology) Business Description

Traded in Other Exchanges
Address
25B Vreeland Road, Suite 300, Florham Park, NJ, USA, 07932
PDS Biotechnology Corp operates as a clinical-stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.
Executives
Spencer D. Brown officer: Senior VP, General Counsel 25B VREELAND ROAD, SUITE 300, FLORHAM PARK NJ 07932
Matthew C Hill officer: Chief Financial Officer C/O STRATA SKIN SCIENCES, INC., 5 WALNUT GROVE DRIVE, SUITE 140, HORSHAM PA 19044
Delyle W Bloomquist director, 10 percent owner RAYONIER ADVANCED MATERIALS INC., 1301 RIVERPLACE BLVD., SUITE 2300, JACKSONVILLE FL 32207
Voorhees Seth Van officer: Chief Financial Officer 12 HARVEY DRIVE, SHORT HILLS NJ 07078
Kamil Ali-jackson director C/O ACLARIS THERAPEUTICS, INC., 101 LINDENWOOD DRIVE, SUITE 400, MALVERN PA 19355
Gregory Gene Freitag director 13631 PROGRESS BLVD., ALACHUA FL 32615
Stephen C. Glover director 108 DOCKSIDE CIRCLE, WESTON FL 33327
Otis W Brawley director 5203 BRISTOL INDUSTRIAL WAY, BUFORD GA 30518
Michael N. King officer: Interim Chief Financial Office 303A COLLEGE ROAD EAST, PRINCETON NJ 08540
Ilian Iliev director 303 A COLLEGE ROAD EAST, PRINCETON NJ 08540
Janetta Trochimiuk officer: Principal Accounting Officer 303A COLLEGE ROAD EAST, PRINCETON NJ 08540
Richard Sykes director C/O PDS BIOTECHNOLOGY CORPORATION, 25B VREELAND ROAD, FLORHAM PARK NJ 07932
Frank Bedu-addo director, 10 percent owner, officer: President/CEO 300 CONNELL DRIVE, SUITE 400, BERKELEY HEIGHTS NJ 07922
Lauren Wood officer: Chief Medical Officer 300 CONNELL DRIVE, SUITE 4000, BERKELEY HEIGHTS NJ 07922
Gregory Conn officer: Chief Scientific Officer 300 CONNELL DRIVE, SUITE 4000, BERKELEY HEIGHTS NJ 07922

PDS Biotechnology (PDS Biotechnology) Headlines